Valuation: 2cureX AB

Market Cap 74.28L 8L 7L 6L 6L 10.83L 7.42Cr 11L 29.04L 3.72Cr 29.21L 28.58L 12Cr P/E 2022
-4.81x
P/E 2023 -1.09x
Enterprise Value -59.75L -6L -5L -5L -5L -9L -5.97Cr -9L -23.35L -2.99Cr -23.5L -22.98L -9.97Cr EV / Sales 2022
29.3x
EV / Sales 2023 7.46x
Free-Float
61.98%
Yield 2022 *
-
Yield 2023 -
1 day-0.25%
1 week-4.94%
Current month-6.48%
1 month-12.46%
3 months-14.41%
6 months-7.13%
Current year+214.40%
1 week 1.58
Extreme 1.578
1.7
1 month 1.58
Extreme 1.578
1.9
Current year 0.52
Extreme 0.52
3.27
1 year 0.51
Extreme 0.514
4.2
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 01/01/2006
Chief Executive Officer 73 -
Chief Executive Officer 50 29/12/2023
Director TitleAgeSince
Chairman 73 16/12/2024
Director/Board Member 67 01/01/2006
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-4.94%-21.93%-60.20% 54.33L
-1.63%+1.20%+96.64%+297.68% 405.21Cr
-3.94%-3.27%+55.16%+76.03% 373.09Cr
+1.77%+51.50%+194.84%-7.65% 293.98Cr
+0.01%+3.58%+278.25%+404.33% 244.34Cr
-2.25%+3.46%-23.79%-31.51% 234.79Cr
-0.47%+6.51%+9.93% - 135.43Cr
-1.84%+14.31%+15.55%+44.24% 104.97Cr
+0.09%-9.28%+116.17%-42.14% 87Cr
-1.62%+8.87%-34.79%-0.85% 57Cr
Average -1.01%+7.48%+68.60%+75.55% 193.61Cr
Weighted average by Cap. -1.26%+9.80%+98.37%+132.75%

Financials

2022 2023
Net sales 33.69L 4L 3L 3L 3L 5L 3.37Cr 5L 13.17L 1.69Cr 13.25L 12.96L 5.62Cr 29.47L 3L 3L 3L 2L 4L 2.94Cr 4L 11.52L 1.47Cr 11.59L 11.34L 4.92Cr
Net income -2.98Cr -31.18L -27.01L -25.31L -23.09L -43.4L -30Cr -44.07L -1.16Cr -15Cr -1.17Cr -1.15Cr -50Cr -3.25Cr -34.06L -29.51L -27.65L -25.22L -47.41L -32Cr -48.14L -1.27Cr -16Cr -1.28Cr -1.25Cr -54Cr
Net Debt -4.49Cr -47.02L -40.74L -38.17L -34.82L -65.45L -45Cr -66.46L -1.75Cr -22Cr -1.77Cr -1.73Cr -75Cr -1.34Cr -14.04L -12.16L -11.4L -10.39L -19.54L -13Cr -19.84L -52.39L -6.7Cr -52.71L -51.56L -22Cr
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
Date Price Change Volume
12/26/12 SEK 1.616 -0.25% 2,851
11/26/11 SEK 1.620 -2.06% 18,779
10/26/10 SEK 1.654 +0.85% 9,217
07/26/07 SEK 1.640 -0.61% 10,577
06/26/06 SEK 1.650 -2.94% 6,442
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock